Targeting Angiogenesis, Enhancing Radiosensitization and Crossing the Blood–Brain Barrier for Brain Metastases

Introduction

Brain metastases (BM) constitute a significant disease burden and have a major impact on patient morbidity and mortality ( ). Recent progress in the preclinical and clinical development of molecular targeted drugs has revealed that some of them have potent therapeutic efficacy for BM. Here the preclinical and clinical knowledge on the role of targeting angiogenesis in BM is discussed. In addition, the potential of sensitizing BM to radiation and increasing blood–brain barrier penetrability to improve the outcome of this devastating disease is examined.